{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-039072","form_type":"8-K","ticker":"ANNX","cik":"0001528115","company_name":"Annexon, Inc.","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.205906+00:00","generated_at":"2026-06-12T04:13:28.978834+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Annexon Q2 net loss $35.2M; GA visual function data; GBS enrollment completion in H2 2023","bullets":["ANX007 (GA) ARCHER Phase 2 data showed dose-dependent preservation of visual function; regulatory engagement planned.","Phase 3 pivotal trial of ANX005 in GBS enrollment to complete in H2 2023; topline results expected H1 2024.","Appointed Jamie Dananberg, M.D., as CMO; brings >20 years of drug development experience.","Cash and equivalents $192.9M as of June 30, providing runway into 2025. Q2 net loss $35.2M ($0.47 per share).","Upcoming catalysts: ANX1502 Phase 1a data (H2 2023), ANX009 LN Phase 1b data, ALS Phase 2a data."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-039072","json":"https://secwatch.observer/filing/0000950170-23-039072.json","markdown":"https://secwatch.observer/filing/0000950170-23-039072.md","text":"https://secwatch.observer/filing/0000950170-23-039072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528115/000095017023039072/0000950170-23-039072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528115/000095017023039072/annx-20230807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T04:13:28.978834+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf7b5c65f58a8a76436d28c2b48c5db4a6398177","claim":"Annexon, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss was $35.2 million or $0.47 per share for the quarter ended June 30, 2023, EPS $0.47 per share.","evidence_excerpt":"Annexon, Inc. (the “Company”) announced certain financial results for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1528115/000095017023039072/0000950170-23-039072-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss was $35.2 million or $0.47 per share for the quarter ended June 30, 2023"},{"label":"EPS","value":"$0.47 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}